[
  {
    "title": "2 Beaten-Down Stocks to Buy on the Dip",
    "published": 1742673840
  },
  {
    "title": "Amicus Therapeutics (FOLD) Up 0.1% Since Last Earnings Report: Can It Continue?",
    "published": 1742571030,
    "posting_price": 505.42001343,
    "close_price": 503.20001221,
    "percent_change": -0.43923888
  },
  {
    "title": "As The Biotech Sector Remains Strong, Vertex Stock Trades Near Buy Point",
    "published": 1742558455,
    "posting_price": 505.42001343,
    "close_price": 503.20001221,
    "percent_change": -0.43923888
  },
  {
    "title": "Q4 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks",
    "published": 1742461970,
    "posting_price": 509.98999023,
    "close_price": 510.17999268,
    "percent_change": 0.03725611
  },
  {
    "title": "CRISPR Therapeutics AG (CRSP): A Bull Case Theory",
    "published": 1742391707,
    "posting_price": 512.01000977,
    "close_price": 512.52001953,
    "percent_change": 0.09960933
  },
  {
    "title": "Vertex Up 25% YTD: Should You Buy, Sell or Hold the Stock?",
    "published": 1742222820,
    "posting_price": 505.20001221,
    "close_price": 513.76000977,
    "percent_change": 1.69437794
  },
  {
    "title": "3 Unstoppable Stocks You Can Buy Now Without Any Hesitation",
    "published": 1742208420,
    "posting_price": 505.20001221,
    "close_price": 513.76000977,
    "percent_change": 1.69437794
  },
  {
    "title": "Why Is Alkermes (ALKS) Down 6.6% Since Last Earnings Report?",
    "published": 1741966234,
    "posting_price": 507.0,
    "close_price": 504.76998901,
    "percent_change": -0.43984438
  },
  {
    "title": "3 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now",
    "published": 1741945860,
    "posting_price": 507.0,
    "close_price": 504.76998901,
    "percent_change": -0.43984438
  },
  {
    "title": "GILD vs. VRTX: Which Stock Is the Better Value Option?",
    "published": 1741880408,
    "posting_price": 493.79000854,
    "close_price": 502.92001343,
    "percent_change": 1.84896509
  },
  {
    "title": "Vertex Pharma scientist talks about the long road to developing non-addictive painkillers",
    "published": 1713196841,
    "posting_price": 400.0,
    "close_price": 397.35998535,
    "percent_change": -0.66000366
  },
  {
    "title": "Here's (at Least) 1 new Reason to Buy Vertex Pharmaceuticals Stock",
    "published": 1713186900,
    "posting_price": 400.0,
    "close_price": 397.35998535,
    "percent_change": -0.66000366
  },
  {
    "title": "Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know",
    "published": 1713186250,
    "posting_price": 400.0,
    "close_price": 397.35998535,
    "percent_change": -0.66000366
  },
  {
    "title": "Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), Vertex Pharmaceuticals (VRTX) and Amgen (AMGN)",
    "published": 1713163260,
    "posting_price": 400.0,
    "close_price": 397.35998535,
    "percent_change": -0.66000366
  },
  {
    "title": "TD Cowen says sickle cell therapies may get higher CMS payments",
    "published": 1713153180,
    "posting_price": 400.0,
    "close_price": 397.35998535,
    "percent_change": -0.66000366
  },
  {
    "title": "Novartis reports results from interim analysis of Phase 3 APPLAUSE-IgAN study",
    "published": 1713143160,
    "posting_price": 400.0,
    "close_price": 397.35998535,
    "percent_change": -0.66000366
  },
  {
    "title": "3 Magnificent Stocks That Could Double or More by 2030",
    "published": 1713012420
  },
  {
    "title": "Could This Stock Be the Next Biotech Buyout?",
    "published": 1713000540
  },
  {
    "title": "Alpine (ALPN) Surges 37% on $4.9B Buyout Offer From Vertex",
    "published": 1712939760,
    "posting_price": 396.57000732,
    "close_price": 396.54998779,
    "percent_change": -0.00504817
  },
  {
    "title": "Health Care Roundup: Market Talk",
    "published": 1712933700,
    "posting_price": 396.57000732,
    "close_price": 396.54998779,
    "percent_change": -0.00504817
  },
  {
    "title": "Buy Rating Affirmed: Vertex Pharmaceuticals\u2019 Strategic Acquisition and Market Positioning Promise Growth",
    "published": 1712925660,
    "posting_price": 396.57000732,
    "close_price": 396.54998779,
    "percent_change": -0.00504817
  },
  {
    "title": "Analysts Offer Insights on Healthcare Companies: Catalent (CTLT), Vertex Pharmaceuticals (VRTX) and Alkermes (ALKS)",
    "published": 1712925660,
    "posting_price": 396.57000732,
    "close_price": 396.54998779,
    "percent_change": -0.00504817
  },
  {
    "title": "Analyst Maintains \u2018Sell\u2019 Rating on Vertex Pharmaceuticals Amid Skepticism Over Alpine Acquisition and Early-Stage Data",
    "published": 1712925420,
    "posting_price": 396.57000732,
    "close_price": 396.54998779,
    "percent_change": -0.00504817
  },
  {
    "title": "The Analyst Landscape: 16 Takes On Vertex Pharmaceuticals",
    "published": 1712923440,
    "posting_price": 396.57000732,
    "close_price": 396.54998779,
    "percent_change": -0.00504817
  },
  {
    "title": "Biotech Alert: Searches spiking for these stocks today",
    "published": 1712916540,
    "posting_price": 396.57000732,
    "close_price": 396.54998779,
    "percent_change": -0.00504817
  },
  {
    "title": "Vertex Pharmaceuticals\u2019 Hold Rating: Balancing Cystic Fibrosis Success with Uncertain Growth from New Acquisition",
    "published": 1712915760,
    "posting_price": 396.57000732,
    "close_price": 396.54998779,
    "percent_change": -0.00504817
  },
  {
    "title": "ClearBridge Aggressive Growth Strategy Q1 2024 Portfolio Manager Commentary",
    "published": 1712906400,
    "posting_price": 396.57000732,
    "close_price": 396.54998779,
    "percent_change": -0.00504817
  },
  {
    "title": "Vertex Pharmaceuticals: Alpine Accelerates Aspiration To Become Biotech Powerhouse",
    "published": 1712898534,
    "posting_price": 396.57000732,
    "close_price": 396.54998779,
    "percent_change": -0.00504817
  },
  {
    "title": "Vertex Pharmaceuticals to buy Alpine Immune Sciences in $4.9B deal",
    "published": 1712867342,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "Stocks to Watch Thursday: Robinhood, Alpine Immune, Constellation Brands",
    "published": 1712843913,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "Alpine: Vertex Acquisition Brings About More Than IgA Nephropathy Advancement",
    "published": 1712854116,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "NEW YORK MARKET CLOSE: Soft PPI spurs tech stocks ahead of earnings",
    "published": 1712852280,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "What Vertex Pharmaceuticals Is Getting With Acquisition Of Alpine Immune Sciences",
    "published": 1712849028,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "Vertex Pharmaceuticals Seeks a Second Act With Alpine Immune Deal. What Wall Street  Says.",
    "published": 1712847780,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "Alpine Catapults 37% After Vertex Pledges $4.9 Billion To Buy It",
    "published": 1712846205,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "Dow Jones Lower Despite PPI Inflation Relief; Nvidia, Microsoft Price Targets Raised",
    "published": 1712845662,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today",
    "published": 1712843276,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "These Stocks Are Moving the Most Today",
    "published": 1712843263,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "Vertex to Pay $4.9 Billion for Kidney Disease Drug Developer",
    "published": 1712842766,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "Vertex Pharmaceuticals: Buy, Sell, or Hold?",
    "published": 1712841300,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "Fastenal, CarMax fall; Alpine Immune Sciences, Arvinas rise, Thursday, 4/11/2024",
    "published": 1712838300,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for April 2024",
    "published": 1712837640,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "What You Missed On Wall Street This Morning",
    "published": 1712833380,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "US STOCKS-Futures slip as rate-cut hopes ebb",
    "published": 1712830642,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "Raymond James Just Raised Its Price Target on Nvidia (NVDA) Stock",
    "published": 1712830140,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "Analyst thinks this drugmaker could be next after Alpine's $4.9B acquisition",
    "published": 1712829000,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "Apple Spyware Warning: What to Know About \u2018Mercenary Spyware Attack\u2019 Alerts",
    "published": 1712828640,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "Vertex To Buy Alpine Immune - Why This Deal Feels Slightly 'Vanilla'",
    "published": 1712828422,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "DoorDash upgraded, Airbnb downgraded: Wall Street's top analyst calls",
    "published": 1712824860,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "Vertex Pharmaceuticals price target raised by $5 at H.C. Wainwright, here's why",
    "published": 1712821380,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "Vertex Pharma upgraded at Evercore on Alpine Immune deal",
    "published": 1712821260,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "Alpine Immune Sciences just downgraded at Leerink, here's why",
    "published": 1712818140,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "Wall Street Braces For Another Red Day Ahead Of More Inflation Data While Bitcoin Holds Above $70K: Analyst Sees Any Pullback As 'Phenomenal Buying Opportunity'",
    "published": 1712817240,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "Vertex Pharmaceuticals (VRTX) Gets a Buy from Piper Sandler",
    "published": 1712816820,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "Stifel Nicolaus Keeps Their Hold Rating on Vertex Pharmaceuticals (VRTX)",
    "published": 1712816760,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "Futures Dip as Treasury Yields Stay High, Fed Rate Cut Hopes Diminish",
    "published": 1712816280,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "Futures slip as rate-cut hopes ebb",
    "published": 1712816242,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "Buy Rating Justified by Vertex Pharmaceuticals\u2019 Strategic Acquisitions and Promising Drug Pipeline",
    "published": 1712815020,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "Tech, Media & Telecom Roundup: Market Talk",
    "published": 1712814840,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "Evercore ISI upgrades Vertex Pharmaceuticals (VRTX) to a Buy",
    "published": 1712813880,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "Evercore expects Vera Therapeutics to trade up on Alpine acquisition news",
    "published": 1712813700,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "Vertex Pharmaceuticals just upgraded at Evercore ISI, here's why",
    "published": 1712813220,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "Drugmakers look to alternative suppliers after draft U.S. legislation, FT says",
    "published": 1712812980,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "Biotech Stocks Heat Up As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options",
    "published": 1712812755,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "Strategic Acquisition and Pipeline Expansion Justify Buy Rating for Vertex Pharmaceuticals",
    "published": 1712811480,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "Analysts Have Conflicting Sentiments on These Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Amylyx Pharmaceuticals Inc (AMLX)",
    "published": 1712809380,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "Buy Rating Affirmed for Vertex Pharmaceuticals Post Alpine Therapeutics Acquisition",
    "published": 1712809020,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "Alpine Immune downgraded to Sector Perform from Outperform at RBC Capital",
    "published": 1712808660,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "M&A: Vertex Bolsters its Drug Portfolio with Alpine Deal",
    "published": 1712807760,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "M&A: Vertex Bolsters its Drug Portfolio with Alpine Immune Deal",
    "published": 1712807580,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "M&A: Vertex Bolsters Drug Pipeline with Alpine Immune Deal",
    "published": 1712807280,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "What You Missed On Wall Street On Thursday",
    "published": 1712805840,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "Stock market today: Wall Street rebounds following its slide as Big Tech takes the reins again",
    "published": 1712803980,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "Vertex's Alpine Acquisition: Unpacking Analyst Predictions on Povetacicept's Potential Impact",
    "published": 1712800380,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "Stocks Bounce Back With Tech, Gold Gaining After Modest Producer Inflation Data: What's Driving Markets Thursday?",
    "published": 1712798220,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "GLOBAL BRIEFING: Chinese inflation cooler than expected in March",
    "published": 1712795400,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "Vertex Pharma\u2019s $4.9 billion takeover of Alpine Immune gives it access to a potential billion-dollar franchise, analyst says",
    "published": 1712793000,
    "posting_price": 399.89001465,
    "close_price": 397.57998657,
    "percent_change": -0.57766586
  },
  {
    "title": "Vertex Pharmaceuticals (VRTX) Registers a Bigger Fall Than the Market: Important Facts to Note",
    "published": 1712786420,
    "posting_price": 399.89001465,
    "close_price": 397.57998657,
    "percent_change": -0.57766586
  },
  {
    "title": "Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion",
    "published": 1712785620,
    "posting_price": 399.89001465,
    "close_price": 397.57998657,
    "percent_change": -0.57766586
  },
  {
    "title": "Vertex Pharmaceuticals Nabs Alpine Immune Sciences In $4.9 Billion Deal",
    "published": 1712783685,
    "posting_price": 399.89001465,
    "close_price": 397.57998657,
    "percent_change": -0.57766586
  },
  {
    "title": "Vertex Pharma bets on kidney disease treatment with $4.9 billion Alpine Immune deal",
    "published": 1712780373,
    "posting_price": 399.89001465,
    "close_price": 397.57998657,
    "percent_change": -0.57766586
  },
  {
    "title": "UPDATE 3-Vertex Pharma bets on kidney disease treatment with $4.9 bln Alpine Immune deal",
    "published": 1712780169,
    "posting_price": 399.89001465,
    "close_price": 397.57998657,
    "percent_change": -0.57766586
  },
  {
    "title": "Vertex Enters Into Agreement to Acquire Alpine Immune Sciences",
    "published": 1712779260,
    "posting_price": 399.89001465,
    "close_price": 397.57998657,
    "percent_change": -0.57766586
  },
  {
    "title": "Vertex to buy kidney disease drugmaker Alpine for $4.9B",
    "published": 1712770440,
    "posting_price": 399.89001465,
    "close_price": 397.57998657,
    "percent_change": -0.57766586
  },
  {
    "title": "Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion -- Update",
    "published": 1712769932,
    "posting_price": 399.89001465,
    "close_price": 397.57998657,
    "percent_change": -0.57766586
  },
  {
    "title": "Vertex Pharma agrees to buy Alpine Immune Sciences for USD4.9 billion",
    "published": 1712766840,
    "posting_price": 399.89001465,
    "close_price": 397.57998657,
    "percent_change": -0.57766586
  },
  {
    "title": "Vertex Pharmaceuticals to buy Alpine Immune Sciences for $4.9 bln",
    "published": 1712765769,
    "posting_price": 399.89001465,
    "close_price": 397.57998657,
    "percent_change": -0.57766586
  },
  {
    "title": "This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?",
    "published": 1712755620,
    "posting_price": 399.89001465,
    "close_price": 397.57998657,
    "percent_change": -0.57766586
  },
  {
    "title": "Analysts\u2019 Top Healthcare Picks: Humacyte (HUMA), Janux Therapeutics Inc (JANX)",
    "published": 1712736660,
    "posting_price": 399.89001465,
    "close_price": 397.57998657,
    "percent_change": -0.57766586
  },
  {
    "title": "Fly Intel: After-Hours Movers",
    "published": 1712723760,
    "posting_price": 399.89001465,
    "close_price": 397.57998657,
    "percent_change": -0.57766586
  },
  {
    "title": "Vertex to acquire Alpine Immune Sciences for $65 per share",
    "published": 1712718120,
    "posting_price": 399.89001465,
    "close_price": 397.57998657,
    "percent_change": -0.57766586
  },
  {
    "title": "Vertex to Announce First Quarter 2024 Financial Results on May 6",
    "published": 1712693100,
    "posting_price": 406.0,
    "close_price": 404.48001099,
    "percent_change": -0.37438153
  },
  {
    "title": "This Growth Stock Is One Step Closer to Launching a New Blockbuster: Time to Buy?",
    "published": 1712671620,
    "posting_price": 406.0,
    "close_price": 404.48001099,
    "percent_change": -0.37438153
  },
  {
    "title": "Better Buy: CRISPR Therapeutics Vs. Viking Therapeutics",
    "published": 1712671200,
    "posting_price": 406.0,
    "close_price": 404.48001099,
    "percent_change": -0.37438153
  },
  {
    "title": "Vortex Energy Gears Up for Pivotal Drilling Phase",
    "published": 1712662800,
    "posting_price": 406.0,
    "close_price": 404.48001099,
    "percent_change": -0.37438153
  },
  {
    "title": "11 Best Biotech ETFs To Buy",
    "published": 1712662637,
    "posting_price": 406.0,
    "close_price": 404.48001099,
    "percent_change": -0.37438153
  },
  {
    "title": "Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.",
    "published": 1712658900,
    "posting_price": 406.0,
    "close_price": 404.48001099,
    "percent_change": -0.37438153
  },
  {
    "title": "Jim Cramer Was Upset At This Hostile Takeover, But 'They Fixed The Situation. Stock's Been A Horse'",
    "published": 1712650620,
    "posting_price": 406.0,
    "close_price": 404.48001099,
    "percent_change": -0.37438153
  },
  {
    "title": "Vortex Energy Announces Drilling Update and $115,500 Grant Award At The Robinsons River Salt Project",
    "published": 1712649600,
    "posting_price": 406.0,
    "close_price": 404.48001099,
    "percent_change": -0.37438153
  },
  {
    "title": "3 High-Growth Biotech Stocks Investors Shouldn\u2019t Sleep On in April",
    "published": 1712642760,
    "posting_price": 406.0,
    "close_price": 404.48001099,
    "percent_change": -0.37438153
  },
  {
    "title": "Analysts Offer Insights on Healthcare Companies: MannKind (MNKD), Vertex Pharmaceuticals (VRTX) and Korro Bio (KRRO)",
    "published": 1712568660,
    "posting_price": 403.45001221,
    "close_price": 404.22000122,
    "percent_change": 0.19085116
  },
  {
    "title": "RBC says pain opinion leader 'notably negative' on Vertex's VX-548",
    "published": 1712567220,
    "posting_price": 403.45001221,
    "close_price": 404.22000122,
    "percent_change": 0.19085116
  },
  {
    "title": "Got $1,000? 2 Bulletproof Stocks to Buy in 2024 and Hold for the Long Haul",
    "published": 1712323800,
    "posting_price": 404.29000854,
    "close_price": 406.67001343,
    "percent_change": 0.58868754
  },
  {
    "title": "Vertex Pharmaceuticals Inc. stock rises Friday, still underperforms market",
    "published": 1712288700,
    "posting_price": 404.29000854,
    "close_price": 406.67001343,
    "percent_change": 0.58868754
  },
  {
    "title": "VRTX May 24th Options Begin Trading",
    "published": 1712225220,
    "posting_price": 412.64001465,
    "close_price": 404.01000977,
    "percent_change": -2.09141251
  },
  {
    "title": "3 Underappreciated Healthcare Stocks to Buy Now: April 2024",
    "published": 1712188946,
    "posting_price": 412.64001465,
    "close_price": 404.01000977,
    "percent_change": -2.09141251
  },
  {
    "title": "Insider Sell: SVP & Chief Accounting Officer Kristen Ambrose Sells Shares of Vertex ...",
    "published": 1712185251,
    "posting_price": 409.45001221,
    "close_price": 408.80999756,
    "percent_change": -0.15631081
  },
  {
    "title": "Vertex Is Worth Your Attention",
    "published": 1712152802,
    "posting_price": 409.45001221,
    "close_price": 408.80999756,
    "percent_change": -0.15631081
  },
  {
    "title": "Truist pharmaceuticals analyst holds an analyst/industry conference call",
    "published": 1712132700,
    "posting_price": 409.45001221,
    "close_price": 408.80999756,
    "percent_change": -0.15631081
  },
  {
    "title": "Vertex (VRTX) Moves Kidney Disease Drug to Phase 3 Development",
    "published": 1712071560,
    "posting_price": 419.0,
    "close_price": 409.42001343,
    "percent_change": -2.28639298
  },
  {
    "title": "Biotech Roundtable: Who will bring the next CRISPR drug to market?",
    "published": 1712054340,
    "posting_price": 419.0,
    "close_price": 409.42001343,
    "percent_change": -2.28639298
  },
  {
    "title": "Vertex Advances Inaxaplin into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease",
    "published": 1712049694,
    "posting_price": 419.0,
    "close_price": 409.42001343,
    "percent_change": -2.28639298
  },
  {
    "title": "Truist Financial Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX)",
    "published": 1712039160,
    "posting_price": 419.0,
    "close_price": 409.42001343,
    "percent_change": -2.28639298
  },
  {
    "title": "Analysts Offer Insights on Healthcare Companies: Smith & Nephew Snats (SNN), Ocuphire Pharma (OCUP) and Vertex Pharmaceuticals (VRTX)",
    "published": 1712038860,
    "posting_price": 419.0,
    "close_price": 409.42001343,
    "percent_change": -2.28639298
  },
  {
    "title": "Analysts Offer Insights on Healthcare Companies: CVS Health (CVS), Vertex Pharmaceuticals (VRTX) and Veeva Systems (VEEV)",
    "published": 1712032320,
    "posting_price": 419.0,
    "close_price": 409.42001343,
    "percent_change": -2.28639298
  },
  {
    "title": "Vertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Here's What You Need to Know",
    "published": 1712008220,
    "posting_price": 420.42999268,
    "close_price": 420.48001099,
    "percent_change": 0.01189694
  },
  {
    "title": "Vertex Announces New Drug Submission for Exagamglogene Autotemcel (exa-cel) Has Been Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia",
    "published": 1711983600,
    "posting_price": 420.42999268,
    "close_price": 420.48001099,
    "percent_change": 0.01189694
  },
  {
    "title": "Missed the \"Magnificent Seven\"? Try Buying These 3 Forever Stocks Instead",
    "published": 1711976400,
    "posting_price": 420.42999268,
    "close_price": 420.48001099,
    "percent_change": 0.01189694
  },
  {
    "title": "Vertex moves kidney disease drug into late-stage testing",
    "published": 1711974180,
    "posting_price": 420.42999268,
    "close_price": 420.48001099,
    "percent_change": 0.01189694
  },
  {
    "title": "Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease",
    "published": 1711972800,
    "posting_price": 420.42999268,
    "close_price": 420.48001099,
    "percent_change": 0.01189694
  },
  {
    "title": "Vertex's NDS for its sickle cell disease and thalassemia treatment accepted for priority review by Health Canada",
    "published": 1711967640,
    "posting_price": 420.42999268,
    "close_price": 420.48001099,
    "percent_change": 0.01189694
  },
  {
    "title": "Vertex announces acceptance of NDS for exagamglogene autotemcel",
    "published": 1711965900,
    "posting_price": 420.42999268,
    "close_price": 420.48001099,
    "percent_change": 0.01189694
  },
  {
    "title": "Meet The \"Magnificent Seven\" of Healthcare Stocks",
    "published": 1711960200,
    "posting_price": 420.42999268,
    "close_price": 420.48001099,
    "percent_change": 0.01189694
  },
  {
    "title": "Vertex Pharmaceuticals advances inaxaplin into Phase 3 portion of trial",
    "published": 1711955460,
    "posting_price": 420.42999268,
    "close_price": 420.48001099,
    "percent_change": 0.01189694
  }
]